USE OF SODIUM-GLUCOSE CO-TRANSPORTER-2 INHIBITOR IS ASSOCIATED WITH LOW RISK OF HEPATIC DECOMPENSATIONS BUT IS NOT AFFECTING DEVELOPMENT OF HEPATOCELLULAR CARCINOMA IN TYPE II DIABETES PATIENTS.

被引：0
|
作者：
Kim, Heaeun [1 ]
Kim, Jin-Wook [1 ]
Park, Jaewon [1 ]
Jang, Sangmi [2 ]
Jeong, Chan Young [1 ]
Choi, Gwang Hyeon [1 ]
Jang, Eun Sun [1 ]
Jeong, Sook-Hyang [1 ]
机构：
[1] Seoul Natl Univ, Coll Med, Dept Internal Med, Bundang Hosp, Seoul, South Korea
[2] Seoul Natl Univ, Bundang Hosp, Seoul, South Korea
来源：
HEPATOLOGY | 2021年 / 74卷
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
1895
引用
收藏
页码：1127A / 1128A
页数：2
相关论文
共 50 条
  • [21] Pharmacokinetics and pharmacodynamics of rongliflozin, a novel selective inhibitor of sodium-glucose co-transporter-2, in people with type 2 diabetes mellitus
    Zhang, Hong
    Zhu, Xiaoxue
    Li, Xiaojiao
    Chen, Hong
    Wu, Min
    Li, Cuiyun
    Liu, Jingrui
    Liu, Chengjiao
    Zhang, Yingjun
    Ding, Yanhua
    DIABETES OBESITY & METABOLISM, 2020, 22 (02): : 191 - 202
  • [22] Possible risk factors for the development of sodium-glucose co-transporter 2 inhibitor-associated diabetic ketoacidosis in type 2 diabetes
    West, Kate
    Webb, Lucy-Anne
    Fenech, Matthew
    Dhatariya, Ketan
    BRITISH JOURNAL OF DIABETES, 2016, 16 (02): : 78 - 81
  • [23] Successful use of the sodium-glucose co-transporter-2 inhibitor dapagliflozin in patients with renal transplant and diabetes: a case series and literature review
    Gul, Wajiha
    Naem, Emad
    Elawad, Safa
    Elhadd, Tarik
    CARDIOVASCULAR ENDOCRINOLOGY & METABOLISM, 2021, 10 (04): : 222 - 224
  • [24] Effects of sodium-glucose co-transporter-2 inhibitors in type 2 diabetes in women versus men
    Radholm, Karin
    Zhou, Zien
    Clemens, Kristin
    Neal, Bruce
    Woodward, Mark
    DIABETES OBESITY & METABOLISM, 2020, 22 (02): : 263 - 266
  • [25] Cardiovascular protection with sodium-glucose co-transporter-2 inhibitors in type 2 diabetes: Does it apply to all patients?
    Giorgino, Francesco
    Vora, Jiten
    Fenici, Peter
    Solini, Anna
    DIABETES OBESITY & METABOLISM, 2020, 22 (09): : 1481 - 1495
  • [26] Clinical considerations when adding a sodium-glucose co-transporter-2 inhibitor to insulin therapy in patients with diabetes mellitus
    Tan, Kathryn
    Chow, W. S.
    Leung, Jenny
    Ho, Andrew
    Ozaki, Risa
    Kam, Grace
    Li, June
    Choi, C. H.
    Tsang, M. W.
    Chan, Norman
    Lee, K. K.
    Chan, K. W.
    HONG KONG MEDICAL JOURNAL, 2019, 25 (04) : 312 - 319
  • [27] Effect of sodium-glucose co-transporter-2 inhibitors on coronary blood flow in patients with type 2 diabetes mellitus
    Tastan, E.
    Soner, S.
    Comert, A. D.
    Altunbas, M.
    Tuzun, R.
    Ozturk, C.
    Akyuz, A.
    Isik, F.
    Cap, M.
    Bilge, O.
    Suleymanoglu, M.
    Oksul, M.
    EUROPEAN REVIEW FOR MEDICAL AND PHARMACOLOGICAL SCIENCES, 2023, 27 (16) : 7620 - 7628
  • [28] Risk of atrial fibrillation development of sodium-glucose co-transporter 2 inhibitor and thiazolidinedione treatment among patients with type 2 diabetes
    Kim, Y. R.
    Lee, S. E.
    Kim, K. A.
    EUROPEAN HEART JOURNAL, 2021, 42 : 460 - 460
  • [29] Use of sodium-glucose co-transporter-2 inhibitors in patients with type 2 diabetes mellitus and multiple cardiovascular risk factors: An Asian perspective and expert recommendations
    Deerochanawong, Chaicharn
    Chan, Siew P.
    Matawaran, Bien J.
    Sheu, Wayne H. -H.
    Chan, Juliana
    Man, Nguyen H.
    Suastika, Ketut
    Khoo, Chin M.
    Yoon, Kun-Ho
    Luk, Andrea
    Mithal, Ambrish
    Ji Linong
    DIABETES OBESITY & METABOLISM, 2019, 21 (11): : 2354 - 2367
  • [30] Sodium-glucose co-transporter-2 (SGLT-2) inhibitors in patients with type 2 diabetes mellitus: the road ahead
    Kramer, Caroline K.
    Zinman, Bernard
    EUROPEAN HEART JOURNAL, 2016, 37 (42) : 3201 - 3202
12345